Abivax (NASDAQ:ABVX) Given New $187.00 Price Target at Citizens Jmp

Posted by Geri Gentry on Jun 3rd, 2026

Abivax (NASDAQ:ABVX – Get Free Report) had its target price raised by research analysts at Citizens Jmp from $131.00 to $187.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 44.19% from the stock’s previous close.

Several other research analysts have also recently commented on ABVX. Jefferies Financial Group cut Abivax from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Tuesday. Barclays upped their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Wedbush upgraded shares of Abivax from an “underperform” rating to a “neutral” rating and lowered their target price for the stock from $110.00 to $90.00 in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.54.

View Our Latest Analysis on Abivax

Abivax Trading Down 2.2%

Shares of ABVX stock opened at $129.69 on Tuesday. The firm’s fifty day moving average price is $118.57 and its two-hundred day moving average price is $120.16. Abivax has a 1 year low of $5.69 and a 1 year high of $148.83. The firm has a market capitalization of $10.34 billion, a P/E ratio of -24.89 and a beta of 0.69.

Abivax (NASDAQ:ABVX – Get Free Report) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities research analysts forecast that Abivax will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several institutional investors and hedge funds have recently modified their holdings of the stock. Avidity Partners Management LP acquired a new stake in shares of Abivax during the 1st quarter worth about $1,114,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 40.9% during the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after buying an additional 213,440 shares during the period. Janus Henderson Group PLC grew its stake in Abivax by 31.6% in the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock valued at $98,007,000 after buying an additional 211,068 shares during the last quarter. Oddo BHF Asset Management Sas raised its holdings in Abivax by 2.7% in the 1st quarter. Oddo BHF Asset Management Sas now owns 81,496 shares of the company’s stock valued at $9,075,000 after acquiring an additional 2,146 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in Abivax in the 1st quarter valued at about $278,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax News Summary

Here are the key news stories impacting Abivax this week:

Positive Sentiment: BTIG Research reaffirmed its buy rating on Abivax and set a $150 price target, implying upside from current levels. BTIG Reaffirms Buy on Abivax
Neutral Sentiment: Wedbush upgraded Abivax from underperform to neutral, but lowered its price target to $90 from $110, signaling caution despite the trial success. Wedbush Upgrades Abivax to Neutral

Abivax Company Profile

(Get Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.